Opinion|Videos|July 19, 2024
ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone
Author(s)Alfred L. Garfall, MD
Alfred L. Garfall, MD, discusses follow-up data from the DREAMM-8 study presented at ASCO 2024.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Discuss the data presented at ASCO 2024 on the DREAMM-8 study (NCT04484623) of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed/refractory multiple myeloma (RRMM). (
Abstract )- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- N=155
- Median follow-up: 21.78 months
- PFS
- ORR
- Median duration of response
- OS
- Safety
- Please provide your key takeaways from this study.How might these findings impact the management of patients with RRMM?
- Belantamab mafodotin was previously withdrawn from the US market for RRMM following results from the phase 3 DREAMM-3 trial (NCT04162210) which did not meet its primary endpoint of progression-free survival (PFS). How do the results of the DREAMM-8 trial shed light on potential advantages of BPd in patients with RRMM?
Advertisement
Related to this article
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
A prospective Italian study of 492 postmenopausal women found ultrasound signs of deep endometriosis in 7.3%, often plaque-like and poorly vascularized.
AHIP's Jeanette Thornton explains where 2027 prior authorization standards fit in the affordability debate and what plans want from Congress.
A new tool puts this year's measles toll at nearly $83 million as global health experts weigh whether the US has lost elimination status.
Earlier Alzheimer disease detection is outpacing specialist capacity and may widen gaps for underserved patients, Cleveland experts say.
Young adults with cancer symptoms often fall outside screening guidelines, face costly imaging, and go undiagnosed longer, oncologists say.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
How Plans, Clinicians Should Handle Gray-Market Retatrutide
3
Early-Onset Cancers Often Found Late as Screening Gaps Persist
4
FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke
5